AlgalR NutraPharms will provide an opportunity to Camlin Fine Sciences for expanding its footprint into the nutraceuticals segment.
The company added that the total cost of the said acquisition shall not exceed Rs 6.50 crore. The cost of acquisition stands at Rs 70 per equity share to be executed in cash within a period of 30 days.
On a consolidated basis, Camlin Fine Sciences' net profit jumped 198.8% to Rs 15.42 crore on a 8.8% rise in net sales to Rs 297.92 crore in Q3 FY21 over Q3 FY20.
Camlin Fine Sciences is a provider of high-quality shelf-life extension solutions including antioxidants, aroma ingredients and performance chemicals.
